Home Page

DALLAS, May 24, 2015 /PRNewswire-iReach/ -- The report "Arrhythmias – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Arrhythmias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arrhythmias and special features on late-stage and discontinued projects.

Photo - http://photos.prnewswire.com/prnh/20150522/218065

An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Arrhythmias may not cause any signs or symptoms. Arrhythmias may be caused by many different factors, including: Coronary artery disease, Electrolyte imbalances in Blood, Changes in heart muscle, Injury from a heart attack, Irregular heart rhythms.

Companies discussed in this Arrhythmias – Pipeline Review, H1 2015 report include:

• Gilead Sciences, Inc.
• Nyken BV
• Orion Oyj
• SciFluor Life Sciences, LLC

Drugs profiles discussed in this report includes GS-967, KN-93, NYK-1112, ORM-10103, PP-1, Small Molecule for Arrhythmia, Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure, Small Molecules to Inhibit Vesicular Acetylcholine Transporter for Arrhythmias, VKII-86. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=365315 . (This is a premium report priced at US$2000 for a single user License.)

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Arrhythmias
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Arrhythmias pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Cardiovascular therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cardiovascular-therapeutics .

More reports on Cardiovascular therapeutics

Pulmonary Arterial Hypertension – Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension. The report reviews key players involved in the therapeutics development for Pulmonary Arterial Hypertension and enlists all their major and minor projects. Companies discussed in this report include Actelion Ltd, APT Therapeutics, Inc., Arena Pharmaceuticals, Inc., Asahi Kasei Pharma Corp., Ascendis Pharma A/S, Bial - Portela & Ca, S.A., Cardioxyl Pharmaceuticals, Inc., Carolus Therapeutics, Inc., Celladon Corporation, Celsion Corporation, Corridor Pharmaceuticals Inc., Cytokinetics, Inc., Eli Lilly and Company, Gilead Sciences, Inc., HanAll Biopharma Co., Ltd., Insmed Incorporated, Ironwood Pharmaceuticals, Inc., Lacer, S.A., Longevity Biotech, Inc, LTT Bio-Pharma Co., Ltd., Mast Therapeutics, Inc., Mezzion Pharma Co. Ltd., miRagen Therapeutics, Inc., Nippon Shinyaku Co., Ltd., Novartis AG, PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc., Pluristem Therapeutics Inc., Proteo, Inc., Reata Pharmaceuticals, Inc., Sagene Pharmaceuticals, Inc., Silence Therapeutics plc, Sinoxa Pharma GmbH, Suda Ltd, Therametrics holding AG, Toray Industries, Inc., United Therapeutics Corporation.

Peripheral Artery Occlusive Disease (PAOD) – Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD). The report provides a snapshot of the global therapeutic landscape of Peripheral Artery Occlusive Disease (PAOD). Companies discussed in this report include Annexin Pharmaceuticals AB, Apceth GmbH & Co. KG, AstraZeneca PLC, Athersys, Inc., Bayer AG, Betagenon AB, Cardiolynx AG, CardioVascular BioTherapeutics, Inc., Celgene Corporation, Cytokinetics, Inc., Diffusion Pharmaceuticals LLC, DNAVEC Corporation, Genovate Biotechnology Co., LTD., Grifols, S.A., Human Stem Cells Institute, Kowa Company, Ltd., Lacer, S.A., Ligand Pharmaceuticals, Inc., LTT Bio-Pharma Co., Ltd., miRagen Therapeutics, Inc., Multi Gene Vascular Systems Ltd, Nuo Therapeutics, Inc., Pluristem Therapeutics Inc., Proteon Therapeutics, Inc., Recardio GmbH, RegenoCELL Therapeutics, Inc., Rigel Pharmaceuticals, Inc., Sagene Pharmaceuticals, Inc., Stemedica Cell Technologies, Inc., Taisho Toyama Pharmaceutical Co., Ltd., Theravasc, Inc., vasopharm GmbH, ViroMed Co., Ltd.

About Us:

RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on sales@rnrmarketresearch.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.

Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnR Market Research